ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

GITR cosignal in ILC2s controls allergic lung inflammation

(2018) Hiroyuki Nagashima et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4

(2018) Sergio A. Quezada et al.   CLINICAL CANCER RESEARCH

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

(2017) Dmitriy Zamarin et al.   Nature Communications

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

ICOS Promotes the Function of CD4+Effector T Cells during Anti-OX40–Mediated Tumor Rejection

(2016) Todd C. Metzger et al.   CANCER RESEARCH

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

ICOS:ICOS-Ligand Interaction Is Required for Type 2 Innate Lymphoid Cell Function, Homeostasis, and Induction of Airway Hyperreactivity

(2015) Hadi Maazi et al.   IMMUNITY

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ICOS Ligation Recruits the p50  PI3K Regulatory Subunit to the Immunological Synapse

(2014) C. Fos et al.   JOURNAL OF IMMUNOLOGY

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer

(2014) YUKI SEO et al.   ONCOLOGY REPORTS

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies

(2014) Andrew J.S. Furness et al.   TRENDS IN IMMUNOLOGY

Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release

(2013) David Eastwood et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer

(2013) Xiao-Mei Huang et al.   CANCER SCIENCE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

(2012) J. Faget et al.   CANCER RESEARCH

After TGN1412: Recent developments in cytokine release assays

(2012) R. Stebbings et al.   Journal of Immunotoxicology

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

B7-H2 Is a Costimulatory Ligand for CD28 in Human

(2011) Sheng Yao et al.   IMMUNITY

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)

(2010) Tyler R Simpson et al.   CURRENT OPINION IN IMMUNOLOGY

Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase

(2009) M. Gigoux et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies

(2008) Zoe Waibler et al.   PLoS One